TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02006602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (GW615775, Test formulation)
Description: Test formulation candesartan cilexetil 16 mg will be supplied as round, biconvex white tablets with PX 16 embossed in one face and scored in the other face.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (GW615775, Test formulation)
Description: Test formulation candesartan cilexetil 16 mg will be supplied as round, biconvex white tablets with PX 16 embossed in one face and scored in the other face.
Study: NCT01527643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 50
Description: A single dose administrated subcutaneously (s.c., under the skin) on two separate dosing visits. A wash-out period of 6-12 days will take place between dosing visits

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 50
Description: A single dose administrated subcutaneously (s.c., under the skin) on two separate dosing visits. A wash-out period of 6-12 days will take place between dosing visits
Study: NCT02963194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Study: NCT04150965

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Elotuzumab, pomalidomide, dexamethasone
Description: Study Patients with relapsed Multiple Myeloma will receive: Elotuzumab, Pomalidomide, and Dexamethasone Starting in Phase 2 Cycle 1 Day 1 forward. Each cycle is 28 days long.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-LAG-3
Description: Patients with relapsed Multiple Myeloma will receive: Anti -LAG-3 single agent for Cycle 1. Each Cycle is 28 days~Cycle 2 forward patients will receive Anti-LAG-3 in combination with pomalidomide and dexamethasone from Cycle 2 forward. Each cycle is 28 days long.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-LAG-3 + Pomalidimide + Dexamethasone
Description: Patients with Relapsed \& Refractory Multiple Myeloma will receive: Anti-LAG-3 in combination with pomalidomide and dexamethasone from Cycle 2 forward. Each cycle is 28 days.
Study: NCT02963194

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01048736

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Only
Description: 4 d/wk of aerobic exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise + Diet
Description: Exercise 4d/wk with moderate caloric restriction (-250 kcal/d deficit) designed for low fat loss (EX+Low CR; \~4.5 kg weight loss).
Study: NCT02006602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (Reference treatment)
Description: Reference treatment of candesartan cilexetil 16 mg will be supplied as round, biconvex pink tablets, scored in one face and with embossment in both faces (016 embossment in the plain face and A CH in the scored face).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (Reference treatment)
Description: Reference treatment of candesartan cilexetil 16 mg will be supplied as round, biconvex pink tablets, scored in one face and with embossment in both faces (016 embossment in the plain face and A CH in the scored face).
Study: NCT01547702

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teacher Help for ADHD
Description: Teachers will review powerpoints other materials online and will have access to a study coach to assist with their understanding and practical application of the materials. Session descriptions follow:~* Session 1: Provide information about ADHD characteristics, impact, diagnosis, etiology~* Session 2: Help establish teacher's role; goal setting; introduce behaviour planning~* Session 3: Help develop and implement behaviour program specific to the needs of students with Session 2 goals~* Session 4: Help develop strategies re: classroom structure, work assignments, teacher-student relationship~* Session 5: Help to use instructional interventions for ADHD~* Session 6: Help to teach these students self-monitoring and self-evaluation skills; help teachers to evaluate progress, phase out behaviour program, and plan for relapses in unwanted behaviours
Study: NCT03423719

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fiit-ns®
Description: Fiit-ns® is a blend of polyphenol-rich extracts from grapefruit, grape, green tea, guarana and black carrot. It also provides Vitamin B3. Daily dosage is 900 mg in two 450 mg-capsules for 16 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo product is 100% maltodextrin. Daily dosage is 900 mg in two 450 mg-capsules of identical appearance than the supplement capsule for 16 weeks.
Study: NCT00313989

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Evaluation of the success rate of implants
Description: Evaluation of the success rate of implants
Study: NCT01048736

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise + Diet
Description: Exercise 4d/wk with intensive caloric restriction (-600 kcal/d deficit) designed for high fat loss (EX+High CR; \~10.9 kg weight loss)
Study: NCT00951665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab emtansine [Kadcyla]
Description: Intravenous escalating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab emtansine [Kadcyla]
Description: Intravenous escalating dose
Study: NCT00841854

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pantoprazole
Description: pantoprazole 40mg bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pantoprazole
Description: pantoprazole 40mg bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bismuth
Description: bismuth 300mg qid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bismuth
Description: bismuth 300mg qid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metronidazole
Description: metronidazole 500mg tid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metronidazole
Description: metronidazole 500mg tid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tetracycline
Description: tetracycline 500mg qid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tetracycline
Description: tetracycline 500mg qid
Study: NCT01888380

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally invasive, virtual autopsy
Description: Post-mortem cross-sectional imaging with CT-guided biopsy
Study: NCT00951665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab emtansine [Kadcyla]
Description: Intravenous escalating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab emtansine [Kadcyla]
Description: Intravenous escalating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Intravenous escalating dose
Study: NCT02754843

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Phonak's equivalent newly developped power BTE

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Phonak's equivalent newly developped power BTE

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Equivalent competitor device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Equivalent competitor device
Study: NCT01163864

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: affect regulation training
Description: 8 sessions of a 1-hour long treatment intended to help women deal more effectively with negative affect; cognitive-behavioral smoking cessation intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: health and lifestyle
Description: 8 sessions of a 1-hour long treatment designed to help women improve their overall health; cognitive-behavioral smoking cessation intervention
Study: NCT03240029

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: SPP questionnaire (Self Perception Profile for Children), Systemic inventory of life quality for children (ISQV-E), Anxiety questionnaire (STAI-C), Depression questionnaire (CDI)
Study: NCT03979599

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levobupivacaine
Description: levobupivacaine
Study: NCT01919736

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Gait Retraining

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Gait Retraining
Study: NCT03147638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin, NOAC
Description: duration of treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin, NOAC
Description: duration of treatment
Study: NCT04150965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-TIGIT
Description: Patients with relapsed Multiple Myeloma will receive: Anti -TIGIT single agent for Cycle 1.~Each cycle is 28 days.
Study: NCT01918449

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical follow up by general practitioners in primary care
Description: The study evaluates two different setting to follow up patients with obstructive sleep apnea on CPAP treatment
Study: NCT04086992

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote monitoring
Description: Caregivers will be able to monitor blood pressure from home and upload in a cloud-based application on a hand-held tablet. In addition, this technology will administer surveys to the caregiver to assess for therapy side effects and adherence. Nurse-led telemedicine visits will also be utilized. The healthcare team will be able to monitor these parameters remotely.
Study: NCT00790478

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: Study Pill (5 mg/d) taken once daily, preferably an hour before bedtime, for 12 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Study Placebo taken once daily, preferably an hour before bedtime, for 12 weeks.
Study: NCT01583816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resiquimod 0.03%
Description: topical application

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resiquimod 0.03%
Description: topical application

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resiquimod 0.03%
Description: topical application

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resiquimod 0.03%
Description: topical application

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resiquimod 0.01%
Description: topical application

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: topical application

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: topical application

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: topical application
Study: NCT03918707

Intervention type: DIAGNOSTIC_TEST
Intervention: Rapid Whole Genome Sequencing (rWGS)
Description: rWGS will be performed on blood samples from subjects in the prospective group in addition to standard of care laboratory testing and imaging studies. Blood samples will also be obtained from biological parents (if available), to determine if variants are inherited or de novo and for variant segregation.
Study: NCT00768482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probuphine (buprenorphine implant)
Description: Implantable formulation of buprenorphine made of buprenorphine HCl/ethylene vinyl acetate, considered a drug. (4 implants)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sublingual Buprenorphine
Description: 16 mg/day, QD
Study: NCT01997190

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdV-tk + valacyclovir
Description: AdV-tk will be administered intrapleural through pleural catheter followed by oral valacyclovir. Valacyclovir will be administered orally at a fixed dose for 14 days after each AdV-tk administration.
Study: NCT03048760

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI scan
Description: All participants will undergo 2 MRI scans - 1 at the time of their radiotherapy planning scans \& 1 after approx. 2 weeks of radiotherapy treatment.
Study: NCT00558272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0530
Description: Daily oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic Acid
Study: NCT02139904

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine
Description: Vinorelbine was first licensed in the UK for Non-Small Cell Lung Cancer (NSCLC) and advanced breast cancer in 1997. Vinorelbine (Navelbine®) is a semi-synthetic, third generation, vinca alkaloid. The cytotoxic effect of vinorelbine is through the disruption of mitotic spindle formation, blocking mitosis at the G2-M stage resulting in cell death.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Active Symptom Control
Study: NCT03871972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Blood Unit
Description: 3 infusions of umbilical cord blood (UCB) unit (TNC \> 2.0ⅹ107cells/kg) each 4 months apart and take oral Sirolimus (1 mg/m2/day) for 7 days (from 3 days before UCB infusion until 3 days after UCB infusion)
Study: NCT04969536

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Branched Chain Amino Acids
Description: Supplementation with 8 g Nutrex Research Amino Acid Drive BCAA in 8 ounces of water once each immediately pre-exercise and after 30 minutes of exercise

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Supplementation with 2.0 milliliters of a sucralose-based drink mix with 8 ounces of water once each immediately pre-exercise and after 30 minutes of exercise
Study: NCT01836393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plavina cream
Description: The essential plai cream has anti-inflammatory and antimicrobial effects (Wasuwat1989, Giwanon 2000, Pithayanukul 2007, and Tripathi 2008). Active chemicals of plai cream are composed of sabinene, alpha and gamma tepinenes, terpinen 4-ol and (E)-1-(3,4-dimethoxyphenyl butadiene (DMPBD). The DMPBD has a property of anti-inflammatory activity(Ozaki 1991, Jeenapongsa 2003). Plavina® 40 mg in 100 gm (contains DMPBD of ...%). This product was supplied in lacquered aluminum collapsible tube containing 100 gram cream packing.
Study: NCT02943616

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Absorb BVS
Description: Commercially approved Absorb GT1 BVS, herein referred to as Absorb.~* Scaffold diameters: 2.5, 3.0, and 3.5 mm~* Scaffold lengths: 8, 12, 18, 23 and 28 mm~Absorb is a temporary scaffold that will fully resorb over time and is indicated for improving coronary luminal diameter in patients with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm.
Study: NCT00951665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Intravenous escalating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Intravenous escalating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Intravenous escalating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab emtansine [Kadcyla]
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab emtansine [Kadcyla]
Description: Intravenous repeating dose
Study: NCT04508374

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 1470 nm intra-lesional diode laser treatment of right HS tunnel
Description: Ten patients: 1470 nm intra-lesional diode laser treatment of right HS-tunnel randomized to active treatment.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 1470 nm intra-lesional diode laser treatment of left HS tunnel
Description: Ten patients: 1470 nm intra-lesional diode laser treatment of left HS-tunnel randomized to active treatment.
Study: NCT01927406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prostaglandin Analog
Description: The first choice drug from group of Prostaglandin Analogues will be bimatoprost, if patient will suffer from any side effect of this drug another drug from this group will be administer. If patient turned out to cannot tolerate the prostaglandin analog therapy then the exclusion criteria will be met.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prostaglandin Analog
Description: The first choice drug from group of Prostaglandin Analogues will be bimatoprost, if patient will suffer from any side effect of this drug another drug from this group will be administer. If patient turned out to cannot tolerate the prostaglandin analog therapy then the exclusion criteria will be met.
Study: NCT04150965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-TIGIT + Pomalidimide + Dexamethasone
Description: Cycle 2 and beyond patients will receive Anti-TIGIT in combination with pomalidomide and dexamethasone from Cycle 2 forward. Each cycle is 28 days..
Study: NCT01888380

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally invasive, virtual autopsy
Description: Post-mortem cross-sectional imaging with CT-guided biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally invasive, virtual autopsy
Description: Post-mortem cross-sectional imaging with CT-guided biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional autopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional autopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional autopsy
Study: NCT01160458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMC-A12
Description: 20 mg/kg intravenous over 60 minutes or not to exceed 25 mg/minute once every 3 weeks (+ or -1 day cycle 3 and beyond)
Study: NCT01901809

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dopamine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dopamine
Study: NCT02745093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: Women at 64-84 days' gestation will use the following dosing regimen: 200 µg mifepristone administered orally in the clinic on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: The client will then be given a total of 2400 µg misoprostol tablets to take home, and will be instructed to take 800 μg misoprostol administered sublingually 24-48 hours later at home and to administer a subsequent dose of 400 μg misoprostol sublingually every 3 hours up to a total of four further doses or until expulsion of the products of conception, whichever comes first.
Study: NCT02142075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daptomycin
Study: NCT02260609

Intervention type: OTHER
Group type: OTHER
Intervention: Grafix®
Description: The treatment indication is for complex diabetic foot wounds with exposed tendon and/or bone that can accommodate up to three 5cm x 5cm pieces of Grafix®.~Patients will be treated for up to 16 weeks.~Patients will be evaluated at screening and then weekly throughout the study or until wound closure.
Study: NCT04885660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: compound lisinopril tablet
Description: The subjects randomly received single oral administration of compound lisinopril tablet(Lisinopril 10mg/Levamlodipine besylate 5mg)
Study: NCT01927406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Timolol
Description: Timolol topical eye drop will be administered in Prostaglandin Analog vs Timolol arm only, in patients with elevated intraocular pressure in both eyes.
Study: NCT00988507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferroquine (SSR97193)
Description: Pharmaceutical form: capsule~Route of administration: oral
Study: NCT00973414

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringer's Lactate
Description: Ringer's Lactate 8 ml/kg was given intravenously before or after CSEA in cesarean section
Study: NCT00988507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferroquine (SSR97193)
Description: Pharmaceutical form: capsule~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferroquine (SSR97193)
Description: Pharmaceutical form: capsule~Route of administration: oral
Study: NCT00973414

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringer's Lactate
Description: Ringer's Lactate 8 ml/kg was given intravenously before or after CSEA in cesarean section

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Six percent hydroxyethyl starch
Description: Hydroxyethyl starch (6%) was given before or after CSEA in cesarean section

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Six percent hydroxyethyl starch
Description: Hydroxyethyl starch (6%) was given before or after CSEA in cesarean section
Study: NCT02416102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg
Description: 50 mg Losartan taken orally once daily for 4 consecutive weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan 50 mg
Description: 50 mg Losartan taken orally once daily for 4 consecutive weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg
Description: 50 mg Losartan taken orally once daily for 4 consecutive weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan 100 mg
Description: 50 mg Losartan taken orally twice daily for 4 consecutive weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan 100 mg
Description: 50 mg Losartan taken orally twice daily for 4 consecutive weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan 100 mg
Description: 50 mg Losartan taken orally twice daily for 4 consecutive weeks.
Study: NCT01037868

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive SMS text messages
Description: Patients in the intervention group would receive twice daily supportive SMS text messages for 3 months from the treating team which would encourage/motivate them to refrain from drinking alcohol and comply with their medication. They would also receive a fortnightly phone call from an unblinded member of the research/treating team which would only serve the purpose of confirming that they still uses the mobile phone and receive the text messages.
Study: NCT04266626

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: kinesiotaping therapy
Description: Kinesiotaping is a new therapeutic technique that gives support to the lip and tongue base muscles without restricting range of motion or blood flow.